Entrada Therapeutics, Inc. (TRDA) · Oct 14, 2026 · Other events

Entrada clinical data shows dystrophin signal but no functional proof

Above the bar — 0.10% mean dystrophin increase vs 0.02% placebo decline

Entrada’s clinical data show favorable safety and early dystrophin production at 5 mg/kg, while higher-dose and functional evidence remain ahead.

Entrada is a clinical-stage biotech building a Duchenne muscular dystrophy franchise around exon-skipping medicines designed for less-frequent dosing; ENTR-601-45 is one of several dose-escalation programs advancing through early human testing. The timing of this readout was already telegraphed, and the independent monitoring committee had already cleared the 10 mg/kg cohort, so the surprise is in the data—not in the event itself.

The study cleared its first hurdle and produced an early pharmacodynamic signal. Cohort 1 met its primary safety and tolerability objectives, while treated participants showed a 0.10% mean increase in dystrophin versus a 0.02% mean decline on placebo, alongside a 0.15% mean increase in exon skipping versus a 0.04% placebo decline. 〔0〕 〔1〕

The signal is encouraging but still below the level needed to establish clinical benefit. Only six treated participants contributed to the dystrophin result, the study has not shown functional outcomes, and the 0.10% mean dystrophin increase is below the stated 0.25% lower limit of quantification; the company also says two treated participants started below that threshold. 〔2〕 That makes this a credible early biological signal, not yet evidence that the therapy improves strength, mobility, or disease progression.

The main business value is that the result supports dose escalation rather than forcing a program reset. All Cohort 1 participants moved into the open-label Phase 2 portion, Cohort 2 is dosing at 10 mg/kg, and the company remains on track to report Cohort 2 data in the first half of 2027; higher exposure is now the key test of whether the modest low-dose signal can become meaningful. 〔3〕 〔4〕

Bottom line: This is better than a bare safety readout because it shows dystrophin production and exon skipping at the starting dose. It advances the program, but the investment-grade proof point remains higher-dose, larger-sample data tied to functional benefit—not this small Cohort 1 result.

What to watch next

Cohort 2 data expected in the first half of 2027

Original filing on SEC EDGAR

More Entrada Therapeutics, Inc. news

• Entrada earnings beat EPS, but revenue misses as runway extends